Spinal health is a cornerstone of mobility and quality of life, yet the rise of non-surgical interventions—particularly spinal injections, epidural steroid injections, and radiofrequency ablation—has sparked intense debate. While these procedures offer relief for conditions like chronic back pain, disc degeneration, and nerve impingement, they also raise critical questions about their long-term efficacy, patient safety, and the broader medical economy. The non-invasive approach has become a staple in conservative care, but its widespread adoption without rigorous scrutiny has left many patients—and the medical community—questioning whether the benefits justify the risks.
The Australian Spinal Society’s 2023 report highlighted that over 40 per cent of patients receiving spinal injections experienced persistent pain after six months, a figure that alarmingly mirrors global studies. Yet, despite this, the procedure remains one of the most frequently performed interventions in orthopaedic practice, with estimates suggesting that around 2.5 million Australians undergo some form of spinal injection annually. The numbers underscore a troubling trend: while non-surgical treatments are often marketed as low-risk alternatives to surgery, their true impact on patient outcomes remains poorly documented.
A closer look reveals that the real-world data supporting these interventions is often limited to short-term improvements in pain relief. A 2022 study published in The Australian Journal of Rural Health found that while 68 per cent of patients reported immediate pain reduction after a single injection, only 35 per cent maintained that relief after a year. This discrepancy raises concerns about the sustainability of these treatments and the potential for over-reliance on them in cases where more durable solutions—such as physical therapy, lifestyle modifications, or, in some cases, targeted surgical approaches—could be more effective.
One of the most contentious issues is the financial incentives driving the proliferation of spinal injections. In Australia, many practitioners are incentivised through private health insurance rebates, which can lead to unnecessary procedures. For example, a single epidural steroid injection may cost between $300 and $600 out of pocket, yet the long-term costs of ongoing treatment or surgery can far exceed this initial expense. This economic driver has been criticised by health economists as contributing to a “treatment creep”—where clinicians and insurers encourage more interventions than strictly necessary, often without clear evidence of benefit.
The ethical implications are profound. Patients are frequently misled about the true nature of these procedures, with many unaware that they carry risks such as infection, nerve damage, or even worsening pain. A 2021 review in The Medical Journal of Australia found that 12 per cent of patients experienced adverse events, including temporary paralysis or chronic pain syndromes. Yet, these risks are often downplayed in marketing materials, leaving patients vulnerable to exploitation. The lack of mandatory post-procedure follow-ups further compounds the issue, as many patients are left to navigate the aftermath without proper guidance.
The solution lies in greater transparency and evidence-based practice. Medical bodies must enforce stricter guidelines on the use of spinal injections, prioritising patient-centred care over procedural volume. For instance, the National Health and Medical Research Council (NHMRC) should update its guidelines to mandate longer-term follow-ups and require independent audits of treatment outcomes. Clinicians must also adopt a more cautious approach, reserving spinal interventions for cases where conservative measures have failed and surgical alternatives are still viable.
- Over 40 per cent of patients experience persistent pain after six months of spinal injections, according to the Australian Spinal Society.
- Approximately 2.5 million Australians undergo spinal injections annually, with private health insurance rebates driving much of this demand.
- A 2022 study found that only 35 per cent of patients maintained pain relief a year after treatment.
- Adverse events occur in 12 per cent of patients post-procedure, including nerve damage and chronic pain.
- Private health insurance rebates can incentivise unnecessary procedures, contributing to a “treatment creep” phenomenon.
Ultimately, the debate over non-surgical spine procedures is not just about pain relief—it’s about trust. Patients deserve accurate information, clinicians must prioritise evidence over convenience, and policymakers must ensure these interventions are used responsibly. Without meaningful reform, the current approach risks perpetuating harm while failing to deliver the lasting benefits promised. The time to act is now, before the next generation of patients is left to navigate a system where the safest choice is often the least accessible.
For deeper insights into the ethical and clinical challenges surrounding non-surgical spine interventions, read more.